Live Breaking News & Updates on Tom Equels

Stay updated with breaking news from Tom equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript

Operator: Hello. And welcome to the AIM ImmunoTech Fiscal Year 2023 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode. ....

United States , Christopher Mcaleer , Jason Mccarthy , James Molloy , Chris Mcaleer , Tom Equels , Thomas Equels , Immunotech Inc , Delaware Supreme Court , Priority Development , Exchange Commission , Maxim Group , Early Access Program , Clinical Cancer Research , University Of Pittsburgh , Alliance Global Partners , Us Erasmus Medical Center , Aerosonic Corp , Chancery Court , Call Transcript April , Tech Fiscal Year , Conference Call , Safe Harbor , Chief Executive Officer , Science Officer , Medical Center ,

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca's Imfinzi for the Treatment of Pancreatic Cancer

OCALA - AIM ImmunoTech Inc. today announced that enrollment is open at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM s Ampligen with AstraZeneca s anti-PD-L1 immune. ....

United States , Thomask Equels , Tom Equels , Jenene Thomas , Exchange Commission , Erasmus Medical Center , Immunotech Inc , Medical Center , Coordinating Investigator , Executive Officer , Big Pharma , Response Evaluation Criteria , Private Securities Litigation Reform Act , News Publishing ,

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer -January 10, 2024 at 08:46 am EST

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla.,. ....

United States , Tom Equels , Thomask Equels , Immunotech Inc , Erasmus Medical Center , Exchange Commission , Coordinating Investigator , Executive Officer Thomas , Big Pharma , Response Evaluation Criteria , Private Securities Litigation Reform Act ,

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer | 10.01.24

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer | 10.01.24
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United States , Tom Equels , Thomask Equels , Erasmus Medical Center , Immunotech Inc , Exchange Commission , Coordinating Investigator , Executive Officer Thomas , Big Pharma , Response Evaluation Criteria , Private Securities Litigation Reform Act ,

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change

/PRNewswire/ Ted D. Kellner, Todd Deutsch and Robert L. Chioini (collectively, the "Kellner Group") today issue the following statement in connection with. ....

New York , United States , New Jersey , William Mitchell , Tom Equels , Robertl Chioini , Stewart Appelrouth , Tedd Kellner , Nancy Bryan , Todd Deutsch , Kazem Kazempour , Okapi Partners , Exchange Commission , Damage The Company , Kellner Group Is Fully , Kellner Group , Us Department Of Justice , Cytodyn Inc , Immunotech Inc , Escalates Unconscionable Waste , Corporate Assets , Act Now Before , Wreckless Spending , Should Not Be Distracted , Misleading Statements , Group Owns ,